Improvement in the survival of children with acute myeloid leukemia at the Colombian National Cancer Institute

Authors

  • Amaranto Suarez Matos Clínica de Oncología Pediátrica, Instituto Nacional de Cancerología, Bogotá D. C., Colombia - Subdirección de investigación, vigilancia epidemiológica, promoción y prevención, Instituto Nacional de Cancerología, Bogotá D. C., Colombia - Servicio de Hematooncología Pediátrica, Facultad de Medicina, Universidad Militar Nueva Granada, Bogotá D. C.
  • Ingrid Aristizábal Clínica de Oncología Pediátrica, Instituto Nacional de Cancerología, Bogotá D. C., Colombia - Servicio de Hematooncología Pediátrica, Facultad de Medicina, Universidad Militar Nueva Granada, Bogotá D. C., Colombia
  • Ana María Infante Clínica de Oncología Pediátrica, Instituto Nacional de Cancerología, Bogotá D. C., Colombia - Servicio de Hematooncología Pediátrica, Facultad de Medicina, Universidad Militar Nueva Granada, Bogotá D. C., Colombia
  • Carlos Narváez Clínica de Oncología Pediátrica, Instituto Nacional de Cancerología, Bogotá D. C., Colombia - Servicio de Hematooncología Pediátrica, Facultad de Medicina, Universidad Militar Nueva Granada, Bogotá D. C., Colombia
  • Luisa Barajas Subdirección de investigación, vigilancia epidemiológica, promoción y prevención, Instituto Nacional de Cancerología, Bogotá D. C., Colombia
  • Martha Piña Clínica de Oncología Pediátrica, Instituto Nacional de Cancerología, Bogotá D. C., Colombia
  • Giovanny Rincón Clínica de Oncología Pediátrica, Instituto Nacional de Cancerología, Bogotá D. C., Colombia - Servicio de Hematooncología Pediátrica, Facultad de Medicina, Universidad Militar Nueva Granada, Bogotá D. C., Colombia
  • Alejandra Calderón Clínica de Oncología Pediátrica, Instituto Nacional de Cancerología, Bogotá D. C., Colombia - Servicio de Hematooncología Pediátrica, Facultad de Medicina, Universidad Militar Nueva Granada, Bogotá D. C., Colombia

DOI:

https://doi.org/10.35509/01239015.16

Keywords:

Acute myeloid leukemia, Child, Mortality, Survival
Abstract References How to Cite

Abstract

Objective: Describe the demographic and clinical characteristics of patients with acute myeloid leukemia, and evaluate the mortality and survival  of children treated with the LMA-INC 2004 protocol (modified from BFM 93) in our pediatric oncology clinic of the National Cancer Institute of Colombia between May 2002 and December 2014.

Patients and methods: Retrospective descriptive observational study of a cohort with survival analysis of patients under 18 years of age with a diagnosis of acute myeloid leukemia treated with intensive chemotherapy without maintenance or transplantation.

Results:  We analyzed 41 patients diagnosed with myeloid leukemia except acute myeloid leukemia type M3, who were, treated with LMA-INC 2004 protocol. Complete remission was achieved in 75.6% of patients. The annual relapse rate was 27.4% and the death rate 20.3%. Cumulative overall survival at 2 and 5 years was 60% and 53.5%, respectively, with an average follow-up of 4.3 years (3.2 - 5.2 years); and the 5-year relapse-free survival was 42% with an average follow-up time of 3.5 years (3.3 - 4.6 years).

Conclusion: The results showed a 30% improvement in the survival of patients with acute myeloid leukemia attributed to a more intense treatment that included the administration of high doses of cytarabine and mitoxantrone in consolidation and intensification; which implies improvement in supportive care.

References

Creutzig U, van den Heuvel-Eibrink M. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood. 2012;120(16):3187-205. https://doi.org/10.1182/blood-2012-03-362608

Rubnitz JE, Inaba H, Riveiro RC. Acute myeloid leukemia. In: Ching-Hon Pui, Editors. Childhood leukemias. Third edition. Cambridge University Press; 2012. p. 395-420. https://doi.org/10.1017/CBO9780511977633.017

Bishop JF, Matthews JP, Young GA, Szer J, Gillett A, Joshua D, et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood. 1996;87(5):1710-7. https://doi.org/10.1182/blood.V87.5.1710.1710

Todd C, Hasle H, Smith F. Acute myeloid leukemia, In: Pizzo PA, Poplack DC, editors. Principles and Practices of Pediatric Oncology. Sixth edition. Philadelphia: Wolters Kluwer; 2011. p. 566-610.

Creutzig U, Zimmermann M, Reinhardt D, Dworzak M, Stary J, Lehrnbecher T. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol. 2004;22(21):4384-93. https://doi.org/10.1200/JCO.2004.01.191

Vizcaíno M. Martínez T. Evaluación del protocolo BFM-93 modificado para MISPHO en niños menores de 15 años con leucemia mieloide aguda en el INC, Bogotá Colombia. Rev Colomb Cancerol. 2003;7(3):11-22.

Weinstein HJ. Acute Myeloid Leukemia. In: Pui CH. Childhood Leukemias. Second edition. Cambridge University Press; 2006. p. 322-35.

Wells RJ, Woods WG, Buckley JD. Treatment of newly diagnosed children and adolescents with acute myeloid leukemia: a Children’s Cancer Group study. J Clin Oncol. 1994;12(11):2367-77. https://doi.org/10.1200/JCO.1994.12.11.2367

Creutzig U, Zimmermann M, Ritter J, Reinhardt D, HermannJ, Henze G, et al. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia. 2005;19(12):2030-42. https://doi.org/10.1038/sj.leu.2403920

Dahl GV, Simone JV, Hustu HO, Mason C. Preventive central nervous system irradiation in children with acute nonlymphocytic leukemia. Cancer. 1978;42(5):2187-92. https://doi.org/10.1002/1097-0142(197811)42:5<2187::AID-CNCR2820420516>3.0.CO;2-Q

Creutzig U, Ritter J, Zimmermann M, Reinhardt D, Hermann J, Berthold F, et al. Improved Treatment Results in High-Risk Pediatric Acute Myeloid Leukemia Patients After Intensification With High-Dose Cytarabine and Mitoxantrone: Results of Study Acute Myeloid Leukemia–Berlin-Frankfurt-Mu¨ nster 93. J Clin Oncol. 2001;19(10):2705-13. https://doi.org/10.1200/JCO.2001.19.10.2705

Creutzig U, Hofmann J, Ritter J, Schellong G. Therapierealisierung und Komplikationen in der Therapiestudie BFM-83 für die akute myeloische Leukämie. Klin Pädiatr. 1988; 200(3):190-9. https://doi.org/10.1055/s-2008-1033708

Arceci RJ, Meshinchi S. Acute Myeloid Leukemia and Myelodysplastic Syndromes. In: Pizzo PA, Poplack DC, editors. Principles and Practices of Pediatric Oncology. Seventh edition. Philadelphia: Wolters Kluwer; 2016. p. 498-544.

Berman JN, Look AT. Pediatric Myeloid Leukemia, Myelodisplasia, and Myeloproliferative Disease. In: Nathan and Oski´s, Editors. Hematology and Oncoloy of Infancy and Chilhood. Eighth edition. Philadelphia: Elsevier; 2015. p. 1555-613.

Balwierz W, Pawinska-Wasikowska K, Klekawka T, Czogala M, Matysiak M, Fic-Sikorska B, et al. Development of treatment and clinical results in childhood acute myeloid leukemia in Poland. Memo. 2013;6(1):54-62. https://doi.org/10.1007/s12254-012-0061-9

Gamis AS, Alonzo TA, Meshinchi S, Sung L, Gerbing RB, Raimondi SC, et al. Gemtuzumab Ozogamicin in Children and Adolescents With De Novo Acute Myeloid Leukemia Improves Event-Free Survival by Reducing Relapse Risk: Results From the Randomized Phase III Children’s Oncology Group Trial AAML0531. J Clin Oncol. 2014;32(27):3021-32. https://doi.org/10.1200/JCO.2014.55.3628

Stevens RF, Hann IM, Wheatley K, Gray RG. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukaemia: Results of the United Kingdom Medical Research Council’s10th AML trial. Br J Haematol. 1998;101(1):130-40. https://doi.org/10.1046/j.1365-2141.1998.00677.x

Büchner T, Hiddemann W, Wörmann B, Löffler H, Gassmann W, Haferlach T, et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood. 1999;93(12):4116-24.

How to Cite

[1]
Suarez Matos, A. et al. 2020. Improvement in the survival of children with acute myeloid leukemia at the Colombian National Cancer Institute. Revista Colombiana de Cancerología. 24, 2 (May 2020), 72–79. DOI:https://doi.org/10.35509/01239015.16.

Downloads

Download data is not yet available.

Downloads

Published

2020-05-26

Issue

Vol. 24 No. 2 (2020)

Section

Research/original articles

License

Todos los derechos reservados. 

Crossref Cited-by logo
2 Cites in Crossref to date